Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CEL | P19835 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27672685 | 0.82 | HTR2C (0.42) | CELPTGDR2HTR2CHTR6 | |
| SCHEMBL533559 | 0.79 | HTR2C (0.46) | CELTDO2HTR2CJAK2JAK1 | |
| SCHEMBL24172412 | 0.77 | BACE1 (0.40) | PTGDR2TDO2JAK2JAK1JAK3 | |
| SCHEMBL534091 | 0.77 | HTR2C (0.47) | CELTDO2HTR2CHTR6 | |
| SCHEMBL28645757 | 0.76 | NUDT1 (0.45) | CELPTGDR2TDO2HTR2CNUDT1 | |
| SCHEMBL8167267 | 0.75 | NOS3 (0.32) | — | |
| SCHEMBL31240954 | 0.74 | HTR2C (0.52) | CELPTGDR2HTR2CHTR6 | |
| Water SCHEMBL7545990 | 0.74 | CYP3A4 (0.38) | CELPTGDR2TDO2HTR2CNUDT1 | |
| SCHEMBL27859396 | 0.74 | CYP3A4 (0.38) | CELPTGDR2TDO2HTR2CNUDT1 | |
| SCHEMBL24749657 | 0.72 | OPRL1 (0.34) | CELHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | CEL 3995/4885PTGDR2 735/4885TDO2 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.